Kubota Pharmaceutical will sell specially designed glasses dubbed Kubota Glass, which it claims are able to reverse the effects of myopia.
The glasses shine tiny lights at the retina to simulate short-distance blurring, forcing the user to look further ahead and in doing so taking the pressure of the axial deformation of eyeballs.
Long-term testing is still required to gauge how effective Kubota Glass is at this in detail, but studies so far suggest that they are at least effective at curbing the progression of myopia.
Kubota Glass has been approved as a medical device in Taiwan and the USA.
Kubota Pharmaceutical charges 770,000 yen for a pair of Kubota Glass while offering a 100-percent satisfaction guarantee.
According to 2009 research conducted by Japan's Ministry of Education, Culture, Sports, Science, and Technology, around 25% of first-graders had less than perfect eyesight, with the percentage rising to 50% among sixth-graders.


Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Indonesia Stocks Face Fragile Sentiment After MSCI Warning and Market Rout
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
India Budget 2025 Highlights Manufacturing Push but Falls Short of Market Expectations
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
U.S.–Venezuela Relations Show Signs of Thaw as Top Envoy Visits Caracas
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast
Canada’s Trade Deficit Jumps in November as Exports Slide and Firms Diversify Away From U.S.
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
China Manufacturing PMI Slips Into Contraction in January as Weak Demand Pressures Economy
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 



